Developing Therapeutics That Teach the Body to Heal Itself
Contributing Author John Vandermosten, Senior Biotechnology Analyst Transaction Trends 2021: Pandora’s Box 2020 was a tremendous year for Initial Public Offerings (IPOs) where 494 new issues came to market[1], but the achievement was eclipsed in 2021 with an all-time record of 1,058 companies going public. In healthcare/life sciences, we counted 118 IPOs in 2020, rising to an impressive 147 in 2021. … [Read More]
Contributing Author John Vandermosten, Senior Biotechnology Analyst Despite the impact of the pandemic and the seemingly solitary focus of the health care machine on addressing SARS-CoV-2, the gene therapy space continued to progress over the last 18 months. Several new approvals were granted and promising candidates were advanced in clinical trials and submitted to regulatory authorities. CAR T has dominated recent… [Read More]
Contributing Author: Gina Hagler The ability to consistently bring treatments and cures to market depends upon a company’s capacity to create and sustain a successful product development pipeline. Traditionally, pharmaceutical companies have developed small molecule medicines such as Zantac or Lipitor to treat conditions such as heartburn or high cholesterol through a trial and error process that begins without… [Read More]
Contributing Author: Gina Hagler Big Picture Gene therapy, stem cell therapy, CAR-T, cell therapy and gene editing are all forms of genomic medicine1 – an approach to cure and treat human diseases that uses human biology rather than chemical compounds made in the lab. All of these tools are unlocking techniques and therapies with the power to cure… [Read More]
Contributing Author: Gina Hagler Gene therapy companies are powering a revolution in rare disease cures by offering treatments that target the genetic cause of the disease. Rather than try different combinations of chemicals to create a small-molecule treatment as is the case with traditional pharmaceuticals, gene therapy uses genetic material in drug development to repair or replace the genetic cause…. [Read More]
Contributing Author: Gina Hagler Pharmaceutical companies have been developing therapies to treat or prevent disease since the end of the 19th century. Chemical compounds are used to create these drugs and medications. The resulting small-molecule drugs – think aspirin – are ingested, metabolized and circulate through the blood. Because it’s not possible to target these drugs, they have a systemic… [Read More]
Contributing Author: Gina Hagler Maryland is home to one of the largest life science clusters in the United States with more than 500 biotech companies. In addition to several state-of-the-art labs, Maryland is home to the NIH in Bethesda. Research opportunities, as well as BS and MS degree programs, are offered at Johns Hopkins in Baltimore and the University of Maryland… [Read More]
Written by Jeff Galvin, CEO of American Gene Technologies® The birth of high-value therapeutics and cures Does the development of effective drugs have to be incredibly expensive? Maybe not anymore. There is a new type of drug development emerging: Gene Therapy. The hallmark of gene therapy is the ability to edit or modify the drivers of disease at the most fundamental… [Read More]
Contributing Author John Vandermosten, Senior Biotechnology Analyst Examining events of the past can give us a sense of what to expect in the periods ahead. And despite the omnipresent warning that “past performance is not indicative of future results” we will share some historical trends on biotech performance surrounding economic contractions that may prove useful in the current environment. The pandemic… [Read More]
Contributing Author John Vandermosten, Senior Biotechnology Analyst Over the last two months nothing has dominated the news as extensively as the coronavirus pandemic which as of March 26th has infected 463,000 people and caused almost 21,000 deaths in in almost every country around the world. The impact from the spread of the virus has impacted not only the health of those… [Read More]
Contributing Author John Vandermosten, Senior Biotechnology Analyst As we enter the twelfth year of an economic expansion, deal activity remains one of the primary ways for large companies to expand both the top and bottom line. One of the dominant industries in the merger and acquisition space has been biotech and life sciences. With scientific breakthroughs coming at an accelerating… [Read More]
Maryland is home to one of the largest life science clusters in the nation. According to the Maryland Department of Commerce, the State has nearly 2,300 life science companies and 476 private research and development biotechnology firms (NAICS 541714), which represents 5.3% of this U.S. industry. Some of the nation’s most important research occurs within Maryland at National Institute of… [Read More]
Subscribe to our newsletter to keep up to date with all the latest news about AGT!